Recursion Pharmaceuticals, Inc. (RXRX) Tops Q4 EPS by 4c

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q4 EPS of ($0.42), $0.04 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $10.89 million versus the consensus estimate of $19.9 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.

You May Also Be Interested In

• Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
• TPU-As-A-Service could boost Google’s 2028 profit by over 15%: Barclays
• Community West Bancshares (CWBC) Misses Q2 EPS by 20c